AML ETO t821 Gene Rearrangement Quantitative MRD Monitor Test sale cost 1220 AED
JAK 2 Mutation Detection Qualitative PCR Test sale cost 1240 AED JAK 2 Mutation Detection Qualitative PCR Test Cost 1,380 د.إ Original price was: 1,380 د.إ.1,240 د.إCurrent price is: 1,240 د.إ.
PML RARA t1517q22q12 Gene Rearrangement Quantitative MRD Monitor Test sale cost 1220 AED PML RARA t1517q22q12 Gene Rearrangement Quantitative MRD Monitor Test Cost 1,350 د.إ Original price was: 1,350 د.إ.1,220 د.إCurrent price is: 1,220 د.إ.
Sale!

AML ETO t821 Gene Rearrangement Quantitative MRD Monitor Test Cost

Original price was: 1,350 د.إ.Current price is: 1,220 د.إ.

-10%

The “AML ETO t(8;21) Gene Rearrangement Quantitative MRD (Minimal Residual Disease) Monitor Test” is a highly specialized diagnostic procedure offered by DNA Labs UAE, aimed at patients with Acute Myeloid Leukemia (AML). This test specifically targets the t(8;21) translocation, a common genetic abnormality found in AML, where parts of chromosomes 8 and 21 are swapped. This rearrangement results in the fusion of two genes, RUNX1 (AML1) and RUNX1T1 (ETO), playing a crucial role in the development and progression of the disease.

The primary purpose of this test is to quantitatively monitor minimal residual disease (MRD) in patients who have previously been diagnosed with AML and have undergone treatment. MRD refers to the small number of cancer cells that may remain in the patient’s body after treatment, which are below the detection level of standard diagnostic methods but can lead to relapse. By precisely measuring the levels of the AML ETO t(8;21) gene rearrangement, the test provides critical information on the effectiveness of treatment and helps in predicting the patient’s prognosis.

The test is conducted using sophisticated molecular techniques that allow for the highly sensitive detection and quantification of the specific gene rearrangement. This makes it an invaluable tool in the management of AML, enabling healthcare providers to tailor treatment strategies based on the individual’s MRD status and to closely monitor for any signs of relapse.

At DNA Labs UAE, the AML ETO t(8;21) Gene Rearrangement Quantitative MRD Monitor Test is priced at 1220 AED. The cost reflects the advanced technology and expertise required to perform this specialized diagnostic procedure, which plays a pivotal role in the personalized care and management of patients with AML.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

AML ETO t821 GENE REARRANGEMENT QUANTITATIVE MRD MONITOR Test

Test Name: AML ETO t821 GENE REARRANGEMENT QUANTITATIVE MRD MONITOR Test

Components: Price 1220.0 AED

Sample Condition: 5 mL (3 mL min.) whole blood / Bone marrow in 1 Lavender Top (EDTA) tube. Ship refrigerated. DO NOT FREEZE.

Duly filled MRD Requisition form (Form 22) with historical data is mandatory.

Report Delivery: SampleMon / Thu by 11 am; Report Wed / Sat

Method: Real Time PCR

Test type: Cancer

Doctor: Hematologist

Test Department: MOLECULAR DIAGNOSTICS

Pre Test Information: Duly filled MRD Requisition form (Form 22) with historical data is mandatory.

Test Details

The AML ETO t(821) gene rearrangement quantitative MRD monitor test is a diagnostic test used in the monitoring of minimal residual disease (MRD) in patients with acute myeloid leukemia (AML) who have the ETO t(821) gene rearrangement.

MRD refers to the small number of cancer cells that may remain in a patient’s body after treatment. Monitoring MRD levels can help determine the effectiveness of treatment and assess the risk of relapse.

The AML ETO t(821) gene rearrangement quantitative MRD monitor test specifically targets the ETO t(821) gene rearrangement, which is a chromosomal abnormality commonly found in AML patients. This test measures the amount of cancer cells with this specific gene rearrangement in a patient’s bone marrow or blood sample.

The test uses quantitative polymerase chain reaction (qPCR) technology to amplify and detect the presence of the ETO t(821) gene rearrangement. The results are reported as a quantitative value, indicating the number of cancer cells with the gene rearrangement per sample.

By monitoring the MRD levels over time, healthcare professionals can assess the response to treatment, detect early signs of relapse, and make informed decisions regarding further treatment strategies for AML patients with the ETO t(821) gene rearrangement.

Test Name AML ETO t821 GENE REARRANGEMENT QUANTITATIVE MRD MONITOR Test
Components
Price 1220.0 AED
Sample Condition 5 mL (3 mL min.) whole blood \/ Bone marrow in 1 Lavender Top (EDTA) tube. Ship refrigerated. DO NOT FREEZE. Duly filled MRD Requisition form (Form 22)with historical data is mandatory.
Report Delivery SampleMon / Thu by 11 am; Report Wed / Sat
Method Real Time PCR
Test type Cancer
Doctor Hematologist
Test Department: MOLECULAR DIAGNOSTICS
Pre Test Information Duly filled MRD Requisition form (Form 22)with historical data is mandatory.
Test Details

The AML ETO t(821) gene rearrangement quantitative MRD monitor test is a diagnostic test used in the monitoring of minimal residual disease (MRD) in patients with acute myeloid leukemia (AML) who have the ETO t(821) gene rearrangement.

MRD refers to the small number of cancer cells that may remain in a patient’s body after treatment. Monitoring MRD levels can help determine the effectiveness of treatment and assess the risk of relapse.

The AML ETO t(821) gene rearrangement quantitative MRD monitor test specifically targets the ETO t(821) gene rearrangement, which is a chromosomal abnormality commonly found in AML patients. This test measures the amount of cancer cells with this specific gene rearrangement in a patient’s bone marrow or blood sample.

The test uses quantitative polymerase chain reaction (qPCR) technology to amplify and detect the presence of the ETO t(821) gene rearrangement. The results are reported as a quantitative value, indicating the number of cancer cells with the gene rearrangement per sample.

By monitoring the MRD levels over time, healthcare professionals can assess the response to treatment, detect early signs of relapse, and make informed decisions regarding further treatment strategies for AML patients with the ETO t(821) gene rearrangement.

SKU: TEST-5629 Category:

Related products